Medtronic plc (MDT) announced on Monday that it has secured CE Mark approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) system and the BrainSense Electrode Identifier in both the European Union and the United Kingdom.
Patients suffering from Parkinson's disease have experienced advantages from deep brain stimulation (DBS), a treatment employing electrical impulses to address neurological disorders. The BrainSense aDBS technology is designed to monitor brain activity and provide real-time stimulation. The BrainSense Electrode Identifier enhances DBS by facilitating faster and more precise initial contact selection during programming.
The company further noted that the first programming with this system was successfully conducted by Martijn Beudel, a neurologist and associate professor at the Department of Neurology, Amsterdam University Medical Center.
Both the BrainSense aDBS and BrainSense Electrode Identifier are expected to become available across Europe later this year. Medtronic has also submitted an application for approval to the U.S. Food and Drug Administration (FDA).
The material has been provided by InstaForex Company -
www.instaforex.com
